• 1. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 2. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 5. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143

• Solvents and Organic Chemicals Organic Compounds Organometallic compounds Organometalloid compounds Tetraorganoarsonium salts
• Solvents and Organic Chemicals Organic Compounds Organometallic compounds Organometalloid compounds Organoarsenic compounds Tetraorganoarsonium salts

Recent Advances in Arsenobetaine Bromide (71642-15-4) Research: A Comprehensive Review

Arsenobetaine bromide (CAS: 71642-15-4) is an organoarsenic compound that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique properties and potential applications. This research briefing aims to provide a comprehensive overview of the latest studies and developments related to this compound, focusing on its synthesis, biological activity, and therapeutic potential. Recent literature highlights the growing interest in arsenobetaine bromide as a candidate for various biomedical applications, including its role in drug delivery systems and as a potential therapeutic agent.

The synthesis of arsenobetaine bromide has been optimized in recent studies, with researchers focusing on improving yield and purity. Advanced chromatographic techniques, such as high-performance liquid chromatography (HPLC), have been employed to characterize the compound, ensuring its structural integrity and consistency. These advancements are critical for its potential use in clinical settings, where purity and reproducibility are paramount. Furthermore, the development of scalable synthetic routes has been a key focus, enabling larger-scale production for preclinical and clinical studies.

In terms of biological activity, arsenobetaine bromide has demonstrated intriguing properties in vitro and in vivo. Studies have shown that it exhibits low toxicity compared to other arsenic-containing compounds, making it a safer alternative for therapeutic applications. Recent research has explored its potential as an anti-inflammatory and anti-cancer agent, with promising results in preclinical models. For instance, arsenobetaine bromide has been shown to modulate key signaling pathways involved in inflammation and cell proliferation, suggesting its potential utility in treating chronic inflammatory diseases and certain types of cancer.

One of the most notable advancements in the field is the exploration of arsenobetaine bromide as a drug delivery vehicle. Its unique chemical structure allows for the conjugation of therapeutic agents, enabling targeted delivery to specific tissues or cells. This approach has been particularly promising in the context of cancer therapy, where targeted delivery can minimize off-target effects and enhance therapeutic efficacy. Recent studies have also investigated its use in combination therapies, where arsenobetaine bromide is co-administered with other drugs to achieve synergistic effects.

Despite these promising developments, challenges remain in the clinical translation of arsenobetaine bromide. Issues such as pharmacokinetics, biodistribution, and long-term safety need to be thoroughly investigated in human trials. Regulatory considerations also play a critical role, as the compound's arsenic content may raise concerns despite its demonstrated low toxicity. Ongoing research is addressing these challenges, with the aim of advancing arsenobetaine bromide toward clinical applications.

In conclusion, arsenobetaine bromide (71642-15-4) represents a promising area of research in the chemical biology and pharmaceutical fields. Its unique properties, low toxicity, and potential therapeutic applications make it a compound of significant interest. Continued research and development efforts are essential to fully realize its potential and overcome existing challenges. This briefing underscores the importance of interdisciplinary collaboration in advancing the understanding and application of arsenobetaine bromide in medicine.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)